Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- the 6th Kitasato University-Harvard School of Public Health Symposium
November 7, 2005
- Japan Lags Behind Other Countries in Terms of Access to New Drugs: OPIR Report
November 7, 2005
- Strengthen Consultation System to Promote Participation in Int'l Clinical Trials: Dr Doi of PMDA
November 7, 2005
- Requirements Relaxed to Facilitate IITs
November 7, 2005
- Korosho to Fund Research Projects to Improve Clinical Research Infrastructure
November 7, 2005
- JMA Pamphlet Questions Need to Control Healthcare Spending
November 7, 2005
- R&D NEWS IN BRIEF
November 7, 2005
- SURVEY 2 articles
November 7, 2005
- IC Tag Commercialization Research Project Invites Members
November 7, 2005
- SymBio to Address "Underserved Therapeutic Areas"
November 7, 2005
- NEW PRODUCTS
November 7, 2005
- Drug Companies to Enjoy Good Results in 1st Half
November 7, 2005
- SEMINAR
November 7, 2005
- Eisai Licenses Vaccine Adjuvant to Sanofi Pasteur
November 7, 2005
- Kyorin Licenses OAB Treatment to LG Life Sciences of South Korea
November 7, 2005
- Pharma Industry Has Steadily Increased Added Value: OPIR Report
November 7, 2005
- MREAC to Review MR Certification, Accreditation Systems
November 7, 2005
- BUSINESS NEWS IN BRIEF
November 7, 2005
- Korosho's Healthcare Reform Proposals Criticized by Prefectural Governor
November 7, 2005
- A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -2-
October 31, 2005
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…